Application 219350
- Type
- ANDA
- Sponsor
- QILU PHARMACEUTICAL CO., LTD.
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | LASMIDITAN | LASMIDITAN | TABLET | 100MG | No | No |
| 002 | LASMIDITAN | LASMIDITAN | TABLET | 50MG | No | No |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Reyvow | LASMIDITAN | Eli Lilly and Company | aea3358c-ff41-4490-9e6d-c7bf7b3de13f | 2026-01-08 | Warnings, Adverse reactions | LASMIDITAN |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Documents#
| Document | Submission type | Date |
|---|---|---|
| 81200 | ORIG | 2025-02-10 |